Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RORC | P51449 | 20/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16632366 | 0.91 | RORC (0.44) | RORC | |
| SCHEMBL16461153 | 0.82 | RORC (0.70) | RORC | |
| SCHEMBL16632824 | 0.81 | RORC (0.49) | RORC | |
| SCHEMBL16632587 | 0.80 | RORC (0.70) | RORC | |
| SCHEMBL16633002 | 0.79 | RORC (0.69) | RORC | |
| SCHEMBL16632780 | 0.72 | RORC (0.50) | RORC | |
| SCHEMBL15202391 | 0.71 | SRD5A2 (0.43) | — | |
| SCHEMBL16641810 | 0.70 | RORC (0.49) | RORC | |
| SCHEMBL16632547 | 0.70 | RORC (0.65) | RORC | |
| SCHEMBL15201993 | 0.69 | SRD5A2 (0.50) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150105351-A1 | COMPOUNDS AND METHODS FOR TREATING HIV INFECTIONS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2015-04-16 | — | — | US | claimed |
| US-20200087264-A1 | NOVEL SELECTIVE LIGAND FOR DOPAMINE D3 RECEPTOR, PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL APPLICATION THEREOF | Shenzhen City Linglan Bio-Pharmaceutical Technology Co., Ltd (CN) | 2020-03-19 | — | — | US | disclosed |
| EP-3560920-A1 | SECONDARY ALCOHOL QUINOLINYL MODULATORS OF ROR GAMMA T | Janssen Pharmaceutica NV (BE) | 2019-10-30 | — | — | EP | disclosed |
| EP-3057949-B1 | SECONDARY ALCOHOL QUINOLINYL MODULATORS OF ROR GAMMA T | JANSSEN PHARMACEUTICA NV (BE) | 2019-06-05 | — | — | EP | disclosed |
| US-9221804-B2 | Secondary alcohol quinolinyl modulators of RORγt | JANSSEN PHARMACEUTICA NV (BE) | 2015-12-29 | — | — | US | disclosed |
| US-9221804-B2 | Secondary alcohol quinolinyl modulators of RORγt | JANSSEN PHARMACEUTICA NV (BE) | 2015-12-29 | — | — | US | disclosed |
| US-9221804-B2 | Secondary alcohol quinolinyl modulators of RORγt | JANSSEN PHARMACEUTICA NV (BE) | 2015-12-29 | — | — | US | disclosed |
| US-20150105372-A1 | SECONDARY ALCOHOL QUINOLINYL MODULATORS OF RORyt | JANSSEN PHARMACEUTICA NV (BE) | 2015-04-16 | — | — | US | disclosed |
| US-20150105372-A1 | SECONDARY ALCOHOL QUINOLINYL MODULATORS OF RORyt | JANSSEN PHARMACEUTICA NV (BE) | 2015-04-16 | — | — | US | disclosed |
| US-20150105372-A1 | SECONDARY ALCOHOL QUINOLINYL MODULATORS OF RORyt | JANSSEN PHARMACEUTICA NV (BE) | 2015-04-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200087264-A1 | NOVEL SELECTIVE LIGAND FOR DOPAMINE D3 RECEPTOR, PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL APPLICATION THEREOF | DRD3, DRD2, PRLHR | RORC 1529/4885 |
| US-20150105372-A1 | SECONDARY ALCOHOL QUINOLINYL MODULATORS OF RORyt | RORC, RORA, RORB | RORC 1/4885 |
| US-20150105351-A1 | COMPOUNDS AND METHODS FOR TREATING HIV INFECTIONS | POLM, POLRMT, DHFR | RORC 1603/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.